Anle138b

CAS No. : 882697-00-9

MCE 站：Anle138b

产品活性：Anle138b 是一种低聚物聚集抑 (oligomeric aggregation ) 调节剂，可阻断朊病毒蛋白 (PrPSc) 和 α-突触核蛋白 (α-syn) 病理性聚集的形成。Anle138b 在体内强烈抑制低聚物积累、神经元变性和疾病进展。Anle138b 毒性低，口服生物利用度高，血脑屏障通透性好。Anle138b 阻断 Aβ 通道并挽救淀粉样变性小鼠模型的疾病表型。

研究领域：Neuronal Signaling

作用靶点：Amyloid-β

In Vitro: Oligomeric aggregates are presumed to be the key neurotoxic agent. Anle138b blocksthe formation of pathological aggregates of prion protein ａnd of α-synuclein, which is deposited in Parkinson’s disease ａnd other synucleinopathies such as dementia with Lewy bodies ａnd multiple system atrophy. Anle138b strongly inhibits all prion strains tested including BSE-derived ａnd human prions. Anle138b shows structure-dependent binding to pathological aggregates ａnd strongly inhibits formation of pathological oligomers both for prion protein ａnd α-synuclein.

In Vivo: Anle138b shows structure-dependent binding to pathological aggregates ａnd strongly inhibits formation of pathological oligomers in vitro ａnd in vivo both for prion protein ａnd α-synuclein.
Anle138b (0.6-2 g/kg; p.o.) modulates α‐synuclein oligomerization.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Neuronal Signaling Compound Library  |  Clinical Compound Library  |  CNS-Penetrant Compound Library  |  Orally Active Compound Library  |  Anti-Alzheimer’s Disease Compound Library  |  Deferoxamine mesylate  |  DAPT  |  β-Amyloid (25-35)  |  FPS-ZM1  |  Colivelin TFA  |  Rutin  |  β-Amyloid (1-42), human TFA  |  20(S)-Ginsenoside Rg3  |  β-Amyloid (1-40)  |  Tolcapone  |  Geniposide  |  Ginsenoside Rg1  |  Licochalcone B  |  β-Amyloid (1-42), rat TFA  |  Semagacestat  |  Latrepirdine dihydrochloride  |  β-Amyloid (42-1), human  |  Dihydroergocristine mesylate  |  Ginsenoside Re  |  Ginsenoside Rg2  |  Hematoxylin  |  Notoginsenoside R1  |  Hoechst 34580 tetrahydrochloride  |  Phenserine  |  Frentizole  |  Tramiprosate  |  LX2343  |  Scyllo-Inositol  |  Aftin-4

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。